General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0CTCPW
ADC Name
39914224 Ate-37
Synonyms
Ate-37
   Click to Show/Hide
Organization
ShanghaiTech University.; Shanghai Clinical Research and Trial Center.
Drug Status
Investigative
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Atezolizumab
 Antibody Info 
Antigen Name
Programmed cell death 1 ligand 1 (CD274)
 Antigen Info 
Payload Name
Monomethyl auristatin E
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Phenoxy silyl linker 37
 Linker Info 
Conjugate Type
Site-specific antibody conjugation via engineered cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
4.27
nM
CVCL_0022
Glioblastoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 4.27 nM Positive PD-L1 expression (PD-L1+++/++)
Method Description
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).

   Click to Show/Hide
In Vitro Model Glioblastoma U87 cells CVCL_0022
References
Ref 1 Fine-tuning phenoxy silyl scaffolds for the development of glutathione-responsive prodrugs and antibody-drug conjugates